# China Biosimilar Contract Manufacturing Market > China Biosimilar Contract Manufacturing Market Research Report By Product (Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins), By Production Technology (Mammalian, Non-Mammalian) and By Application (Oncology, Blood Disorders, Growth Hormonal Deficiency, Chronic and amp; Autoimmune Disorders, Rheumatoid Arthritis, Others) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 18.9% - **2024:** $ 405.75 Million - **2025:** $ 482.44 Million - **2035:** $ 2,725.13 Million - **Key Players:** Samsung Biologics (KR), Lonza Group (CH), Boehringer Ingelheim (DE), Fujifilm Diosynth Biotechnologies (JP), Catalent (US), Wuxi Biologics (CN), Rentschler Biopharma (DE), KBI Biopharma (US), Amgen (US) **Report ID:** MRFR/Pharma/50116-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Garvit Vyas · **Last Updated:** February 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/china-biosimilar-contract-manufacturing-market-51874 --- ## Market Summary ## **China Biosimilar Contract Manufacturing Market Overview:** As per MRFR analysis, the China Biosimilar Contract Manufacturing Market Size was estimated at 325.06 (USD Million) in 2023. The China Biosimilar Contract Manufacturing Market Industry is expected to grow from 486.5(USD Million) in 2024 to 3,247 (USD Million) by 2035. The China Biosimilar Contract Manufacturing Market CAGR (growth rate) is expected to be around 18.835% during the forecast period (2025 - 2035). ### **Key China Biosimilar Contract Manufacturing Market Trends Highlighted** Various factors are currently driving a variety of significant trends in the China Biosimilar Contract Manufacturing Market. The ageing population and the increasing prevalence of chronic diseases in China have prompted a significant increase in the demand for affordable healthcare solutions, which is a key market driver. The government's initiatives to promote the development of biosimilars and its emphasis on healthcare reform are further moving this market forward. The National Medical Products Administration (NMPA) has established regulatory pathways and supportive policies that have resulted in a more streamlined process for biosimilar production, thereby fostering a favourable environment for contract manufacturing. Additionally, there are substantial opportunities to be investigated in this market, particularly as Chinese pharmaceutical companies endeavour to broaden their global presence. This trend is demonstrated by the heightened manufacturing capabilities that have been achieved as a result of the increased collaboration between local firms and international organisations for technology transfer. In addition, the development of a diverse portfolio of biosimilars is becoming a priority for companies as competition increases, thereby creating new opportunities for contract manufacturers in China. The trend of Chinese firms increasing their investment in research and development has been gathering momentum in recent years. A strategic emphasis accompanies this on biosimilar development, which has resulted in enhanced product offerings and innovations.Furthermore, the increasing awareness of biosimilars among healthcare professionals and patients is promoting a more positive perception of these products. The transition to personalized medicine also introduces a new dimension to the expansion of biosimilar contract manufacturing in China, as companies endeavor to effectively address the unique requirements of individual patients. In general, the trajectory of the biosimilar contract manufacturing market in China is influenced by the interplay of regulatory support, increasing demand, and innovative practices. Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review** ## **China Biosimilar Contract Manufacturing Market Drivers** ### Increasing Prevalence of Chronic Diseases The rising incidence of chronic diseases such as cancer and diabetes in China is significantly driving the growth of the China Biosimilar Contract Manufacturing Market Industry. According to the National Cancer Center of China, there were approximately 4.58 million new cases of cancer reported in 2020, with projections indicating an increase of 3% annually, which translates to approximately 137,400 additional cases each year. This growing patient population necessitates affordable treatment options, leading to an increased demand for biosimilars.Large pharmaceutical companies, including China National Pharmaceutical Group and Sinopharm, are actively investing in biosimilar development and manufacturing to meet the soaring demands of the healthcare system. These companies are also focusing on enhancing production capabilities to ensure the timely availability of biosimilars in the market. Therefore, the increase in chronic diseases is a pivotal driver for the growth of the China Biosimilar Contract Manufacturing Market. ### Supportive Government Policies The Chinese government is implementing favorable policies and incentives to promote the production and adoption of biosimilars. The government has set a target for the pharmaceutical industry to increase the domestic biosimilar production capacity, aiming for a significant reduction in drug prices. The National Medical Products Administration (NMPA) has introduced streamlined approval processes for biosimilars, cutting the review time from about a decade to less than two years.This regulatory support not only encourages local manufacturers but also attracts foreign investment in the China Biosimilar Contract Manufacturing Market Industry. In line with the Healthy China 2030 initiative, the government is prioritizing cost-effective treatments for its population, thus ensuring sustainable growth in this sector. Technological Advancements in Biomanufacturing Rapid advancements in biomanufacturing technologies are transforming the China Biosimilar Contract Manufacturing Market Industry by increasing efficiency and reducing costs. Innovations such as single-use bioreactors and advanced cell culture techniques are enabling manufacturers to produce biosimilars at a larger scale and lower operational expenses. According to industry analysis, companies leveraging advanced manufacturing technologies have reported a reduction in production costs by up to 30%.Major players such as WuXi AppTec and Innovent Biologics are at the forefront of these technological shifts, investing heavily in Research and Development to enhance their production methods. The adoption of cutting-edge technology in the production of biosimilars is a crucial driver for the market's growth in China. ## **China Biosimilar Contract Manufacturing Market Segment Insights:** ### **Biosimilar Contract Manufacturing Market Product Insights** The China Biosimilar Contract Manufacturing Market has shown substantial growth in its Product segment, reflecting the shifting landscape of biopharmaceutical development in the region. The market is increasingly characterized by a strong focus on Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins, which are pivotal in the production of therapeutic proteins and monoclonal antibodies. Recombinant Non-glycosylated Proteins are often preferred due to their simpler structure, which allows for easier production processes and cost efficiency. At the same time, Recombinant Glycosylated Proteins play a crucial role in ensuring the biological activity and efficacy necessary for complex therapeutic applications.The significance of the Recombinant Non-glycosylated Proteins segment is highlighted by its ability to meet the growing demand for biologics, especially in chronic disease management, where treatment options are expanding. Meanwhile, the increasing investment in Research and Development within China is supporting advancements in glycosylation technologies, positioning Recombinant Glycosylated Proteins as a key competitive edge in achieving product differentiation among biosimilars. With China's commitment to bolstering its biomanufacturing capabilities through favorable government policies and investment in infrastructure, the potential for innovation and growth in these specific product categories will drive market dynamics forward.The focus on biosimilars not only addresses the need for cost-effective alternatives to expensive biologics but also aligns with the country's healthcare objectives of improving accessibility and patient outcomes. As the Chinese government amplifies its support for the biopharmaceutical sector, enhancing the regulatory framework and encouraging partnerships between industry stakeholders, the Product segment's trajectory appears robust and optimistic. The ongoing evolution of product specifications and compliance within the regulatory landscape further emphasizes the integral role of these proteins in the overall success of biosimilar manufacturing, spotlighting their importance in shaping the China Biosimilar Contract Manufacturing Market.The market is poised for progressive growth, characterized by ongoing technological advancements, a rising number of production partnerships, and an ever-increasing emphasis on high-quality biopharmaceutical products tailored specifically for the region's diverse healthcare needs. Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review** ### **Biosimilar Contract Manufacturing Market Production Technology Insights** The Production Technology segment of the China Biosimilar Contract Manufacturing Market plays a pivotal role in the industry's growth trajectory, driven by an increasing demand for biologics and biopharmaceuticals within the region. The distinction between Mammalian and Non-Mammalian production technologies reflects the diverse methodologies employed in biosimilar production. Mammalian systems, which include cell cultures such as Chinese Hamster Ovary cells, are heralded for their ability to produce complex proteins that closely mimic human biology, making them essential for many biosimilar products. In contrast, Non-Mammalian systems, such as microbial fermentation, offer faster production cycles and cost efficiencies, catering to less complex biosimilars. This production flexibility enables manufacturers to meet diverse market needs effectively, providing opportunities for both large-scale commercial production and niche market segments. As China continues to bolster its biopharmaceutical sector through supportive regulations and industry initiatives, the integration of advanced production technologies is expected to further enhance the efficiency and quality of biosimilar manufacturing, ultimately strengthening the nation's position in the global biosimilar market landscape.Overall, the ever-evolving Production Technology innovations underscore the importance of strategic investments in R&D and manufacturing capabilities, setting the foundation for future market advancements. ### **Biosimilar Contract Manufacturing Market Application Insights** The Application segment of the China Biosimilar Contract Manufacturing Market includes vital areas such as Oncology, Blood Disorders, Growth Hormonal Deficiency, Chronic and Autoimmune Disorders, Rheumatoid Arthritis, and others. Oncology is particularly significant, driven by the increasing prevalence of cancer within China, which has prompted the demand for innovative therapies that biosimilars can provide. Blood Disorders represent a major component of this market due to the rising incidence of conditions that require complex treatments, encouraging growth in contract manufacturing to meet production needs. The focus on Growth Hormonal Deficiency highlights the ongoing advancements in endocrinology and the demand for effective hormone therapies. Chronic and Autoimmune Disorders, alongside Rheumatoid Arthritis, showcase the necessity for cost-effective medication options as these conditions affect a large segment of the population, increasing pressure to provide accessible treatments. Overall, these areas collectively illustrate the growing importance of biosimilars within China’s healthcare landscape, driven by significant patient needs and the increasing acceptance of biosimilars among healthcare providers and patients alike.The China Biosimilar Contract Manufacturing Market is poised for development as these application areas expand, unveiling opportunities for contract manufacturers to enhance production capabilities and meet market demands effectively. ### **China Biosimilar Contract Manufacturing Market Key Players and Competitive Insights:** The China Biosimilar Contract Manufacturing Market has seen significant growth as the demand for affordable biopharmaceuticals continues to rise. This competitive landscape is characterized by a mix of established local players and multinational corporations seeking to capitalize on China's expanding healthcare needs. Several factors, including regulatory frameworks, technological advancements, and strategic partnerships, shape the market. Key stakeholders are focused on optimizing production processes, enhancing product quality, and ensuring compliance with stringent regulations. Companies are also increasingly engaging in collaborations and joint ventures to leverage respective strengths and expand their market reach. This dynamic environment allows for ongoing innovation and competition, positioning the China Biosimilar Contract Manufacturing Market as a crucial component of the global biopharmaceutical sector.Changchun High & New Technology Industry has established a robust presence in the China Biosimilar Contract Manufacturing Market by leveraging its advanced technological capabilities and a strong commitment to quality. The company specializes in the development and production of biosimilars that meet the growing demands for more affordable treatment options in the biopharmaceutical sector. With a focus on research and development, Changchun High & New Technology Industry has cultivated strategic partnerships with various healthcare providers and research institutions, enhancing its market position. The company’s state-of-the-art facilities and experienced workforce enable it to effectively navigate complex manufacturing processes while ensuring compliance with regulatory standards. This well-rounded approach has contributed to its reputation as a reliable partner in the biosimilar manufacturing space in China.Livzon Pharmaceutical stands out in the China Biosimilar Contract Manufacturing Market due to its comprehensive portfolio of biosimilars and a strong focus on innovation and quality. The company offers a diverse range of key products and services, including various biosimilars for therapeutic applications, targeted specifically towards the Chinese healthcare market. Livzon Pharmaceutical has made significant strides in establishing its production capabilities and enhancing its market presence through strategic initiatives. The company's strengths lie in its commitment to research and development, which has led to important breakthroughs in biosimilar production. Furthermore, Livzon Pharmaceutical has pursued various mergers and acquisitions to bolster its manufacturing infrastructure and expand its product offerings. These efforts not only strengthen its position in the highly competitive market but also enhance its ability to meet the evolving demands of patients and healthcare providers across China. ### **Key Companies in the China Biosimilar Contract Manufacturing Market Include:** ## **China Biosimilar Contract Manufacturing Market Industry Developments** Recent developments in the China Biosimilar Contract Manufacturing Market have highlighted significant activities among key players. In July 2023, Changchun High and New Technology Industry announced the expansion of its biosimilar production facilities to enhance its manufacturing capacity, driven by increasing global demand for affordable biologics. Livzon Pharmaceutical continues to invest in Research and Development to strengthen its biosimilar portfolio, particularly in oncology products. WuXi AppTec has recently forged partnerships with international biopharmaceutical companies to facilitate clinical trials for multiple biosimilars. Additionally, in August 2023, Qilu Pharmaceutical reported a collaboration with Samsung BioLogics focused on the production of monoclonal antibodies, aiming to expand in the global biosimilar market. Notably, in March 2022, Hualan Biological Engineering completed the acquisition of a majority stake in ST Pharm, enhancing its capabilities in biosimilar production. The biosimilar market in China is projected to grow substantially, powered by advancements in technology and increased regulatory support from the National Medical Products Administration, fostering a more competitive landscape. Despite challenges, the push towards affordable therapeutics is reshaping the market, positioning companies like 3SBio and HengRui Medicine favorably for future opportunities. ## **China Biosimilar Contract Manufacturing Market Segmentation Insights** ### **Biosimilar Contract Manufacturing Market Product****Outlook** ### **Biosimilar Contract Manufacturing Market Production Technology****Outlook** ### **Biosimilar Contract Manufacturing Market Application****Outlook** ## Market Drivers ### Growing Aging Population The growing aging population in China is a significant driver for the biosimilar contract-manufacturing market. With an estimated 300 million individuals aged 60 and above by 2025, the demand for biologic therapies is expected to surge. Older adults are more susceptible to chronic diseases, necessitating effective and affordable treatment options. Biosimilars, which offer similar efficacy to their reference products at lower costs, are likely to become increasingly popular among healthcare providers. This demographic shift suggests that the biosimilar contract-manufacturing market will experience heightened activity as manufacturers strive to meet the needs of this expanding patient population. The market could see a growth rate of approximately 15% annually, driven by the increasing prevalence of age-related health conditions. ### Supportive Government Policies Supportive government policies play a crucial role in shaping the biosimilar contract-manufacturing market. The Chinese government has implemented various initiatives aimed at promoting the development and adoption of biosimilars. For instance, the introduction of the National Medical Products Administration (NMPA) guidelines has streamlined the approval process for biosimilars, making it easier for manufacturers to enter the market. Additionally, the government has established financial incentives for companies investing in biosimilar production, which could potentially enhance the market's growth. As of 2025, it is estimated that around 30% of new biologics approvals in China will be for biosimilars, indicating a robust policy environment that favors the expansion of the biosimilar contract-manufacturing market. ### Increasing Healthcare Expenditure The rising healthcare expenditure in China is a pivotal driver for the biosimilar contract-manufacturing market. As the government allocates more funds towards healthcare, the demand for affordable treatment options intensifies. In 2025, healthcare spending in China is projected to reach approximately $1 trillion, reflecting a growth rate of around 10% annually. This increase in expenditure is likely to encourage healthcare providers to seek cost-effective biosimilars, thereby boosting the contract-manufacturing sector. Furthermore, the emphasis on universal healthcare coverage in China may lead to a greater reliance on biosimilars, as they offer similar therapeutic benefits at reduced costs. Consequently, the biosimilar contract-manufacturing market is expected to expand as manufacturers align their production capabilities to meet this growing demand. ### Increased Focus on Research and Development Increased focus on research and development (R&D) within the biopharmaceutical sector is a vital driver for the biosimilar contract-manufacturing market. Companies are investing heavily in R&D to develop new biosimilar products that can address unmet medical needs. In 2025, R&D spending in China's biopharmaceutical industry is projected to reach approximately $50 billion, reflecting a commitment to innovation. This investment is likely to result in a surge of new biosimilar candidates entering the market, which will require robust contract-manufacturing capabilities. As firms seek to expedite the development process and bring products to market efficiently, the biosimilar contract-manufacturing market is expected to benefit from increased demand for specialized manufacturing services. ### Rising Competition Among Biopharmaceutical Companies Rising competition among biopharmaceutical companies is another key driver influencing the biosimilar contract-manufacturing market. As more companies enter the biosimilar space, the need for efficient and cost-effective manufacturing solutions becomes paramount. This competitive landscape encourages innovation and collaboration, leading to advancements in manufacturing technologies and processes. In 2025, it is anticipated that the number of biosimilar products in the Chinese market will exceed 100, prompting contract manufacturers to enhance their capabilities to meet diverse client needs. The pressure to reduce production costs while maintaining quality standards may drive contract manufacturers to adopt more sophisticated technologies, thereby fostering growth in the biosimilar contract-manufacturing market. ## Future Outlook The [Biosimilar Contract Manufacturing Market](https://www.marketresearchfuture.com/reports/biosimilar-contract-manufacturing-market-11903) is projected to grow at 18.9% CAGR from 2025 to 2035, driven by increasing demand for affordable biologics and regulatory support. **New opportunities:** - Establishing strategic partnerships with local biotech firms for co-development projects. - Investing in advanced bioprocessing technologies to enhance production efficiency. - Expanding service offerings to include regulatory compliance consulting for biosimilar approvals. By 2035, the market is expected to achieve substantial growth, positioning itself as a leader in biopharmaceutical manufacturing. ## Segment Insights ### By Product: Recombinant Glycosylated Proteins (Largest) vs. Recombinant Non-glycosylated Proteins (Fastest-Growing) In the China biosimilar contract-manufacturing market, the distribution of market share among product segments reveals a significant lead for recombinant glycosylated proteins, which dominate the landscape due to their extensive application in therapeutic areas. The demand for these proteins is driven by the increasing need for complex biopharmaceuticals that require advanced manufacturing capabilities, allowing for widespread adaptation across various healthcare settings. On the other hand, recombinant non-glycosylated proteins are recognized as the fastest-growing segment, fueled by advancements in technology and an increasing number of approved biosimilars. This growth is attributable to their relatively simpler production processes and lower costs, making them attractive alternatives in treating various conditions, thus capturing a growing share of the market as manufacturers expand their portfolios to include these products. Recombinant Glycosylated Proteins (Dominant) vs. Recombinant Non-glycosylated Proteins (Emerging) Recombinant glycosylated proteins are characterized by their complex structures and essential roles in biopharmaceutical production, representing the dominant force in the market. Their intricate glycosylation patterns enhance therapeutic efficacy, making them crucial for treatments in oncology and autoimmunity. In contrast, recombinant non-glycosylated proteins are emerging as significant contenders, primarily due to their more straightforward production methodologies. These proteins cater to a growing demand for cost-effective therapeutic solutions and have seen increased investment from manufacturers seeking to leverage their rapid development cycles. As advancements continue in production techniques, both segment values are poised to play vital roles in shaping the future landscape of the biosimilar contract-manufacturing market. ### By Production Technology: Mammalian (Largest) vs. Non-Mammalian (Fastest-Growing) In the Production Technology segment of the China biosimilar contract-manufacturing market, Mammalian technologies hold the largest share, driven by their ability to produce complex therapeutic proteins with post-translational modifications. This technology is highly preferred for monoclonal antibodies and other biologics, making it a dominant player in the market. In contrast, Non-Mammalian technologies, including microbial systems, have been gaining traction due to their advantages in speed and cost-efficiency, albeit they currently hold a smaller market share. The growth trends in this segment reveal a robust demand for Mammalian systems, supported by increasing investments in R&D and a rising number of biopharmaceutical approvals. However, Non-Mammalian technologies are seen as the fastest-growing segment due to their potential for rapid scalability and shorter production times. The shift towards biosimilar production is driven by a need for cost-effective alternatives to expensive biologics, positioning Non-Mammalian technology as a key player for the future. Production Technology: Mammalian (Dominant) vs. Non-Mammalian (Emerging) Mammalian production technology stands as the dominant force in the China biosimilar contract-manufacturing market, celebrated for its ability to produce high-quality biologics that closely mimic human proteins. This segment benefits from established manufacturing practices and regulatory approvals, ensuring reliability and extensive application in producing complex molecules such as monoclonal antibodies. Conversely, Non-Mammalian technology represents an emerging alternative, particularly in the production of simpler proteins. Its capacity for high-speed production and lower operating costs aligns well with industry demands for more efficient and economical manufacturing solutions. As the market evolves, Non-Mammalian systems are expected to capture an increasing share due to their agility and potential for innovation in a rapidly changing biosimilars landscape. ### By Application: Oncology (Largest) vs. Chronic & Autoimmune Disorders (Fastest-Growing) The application segment of the China biosimilar contract-manufacturing market reveals a diverse distribution of market shares among various segments. Oncology remains the largest segment, driven by an increasing prevalence of cancer and an expanding range of biosimilars developed for cancer treatment. Other pivotal segments include blood disorders and chronic & autoimmune disorders, each holding substantial shares, resulting in a competitive landscape that favors innovation and patient-centric solutions. Growth trends indicate that chronic & autoimmune disorders are emerging as the fastest-growing segment within this market, propelled by rising incidences of autoimmune diseases and the growing awareness of biosimilars as cost-effective treatment options. The oncology segment, while dominating, continues to evolve with advanced therapies and targeted treatments, creating opportunities for contract manufacturers to enhance their capabilities to meet specific client needs and regulatory standards. Oncology: Dominant vs. Chronic & Autoimmune Disorders: Emerging The oncology segment stands as a dominant force in the China biosimilar contract-manufacturing market, characterized by a robust pipeline of biosimilar products tailored for oncology treatments. This dominance is attributed to the rapid evolution of cancer therapies and the ongoing need for affordable treatment alternatives. In contrast, chronic & autoimmune disorders represent an emerging segment, showcasing rapid growth fueled by an increasing patient base and heightened demand for effective management strategies. The unique challenges within this segment, including patient variability and the need for personalized treatment approaches, are driving contract manufacturers to innovate and align their services to cater to this expanding market, thus shaping a dynamic future for biosimilar applications. ## Competitive Benchmarking The biosimilar contract-manufacturing market is currently characterized by a dynamic competitive landscape, driven by increasing demand for cost-effective biologics and the growing acceptance of biosimilars among healthcare providers. Key players such as Wuxi Biologics (China), Samsung Biologics (Korea), and Lonza Group (Switzerland) are strategically positioning themselves through innovation and regional expansion. Wuxi Biologics, for instance, focuses on enhancing its manufacturing capabilities to meet the rising demand, while Samsung Biologics emphasizes its commitment to quality and efficiency in production. Lonza Group, on the other hand, is leveraging its extensive experience in biologics to forge partnerships that enhance its service offerings, thereby shaping a competitive environment that prioritizes quality and reliability.In terms of business tactics, companies are increasingly localizing manufacturing to reduce lead times and optimize supply chains. The market appears moderately fragmented, with several players vying for market share, yet the collective influence of major companies is significant. This competitive structure allows for a diverse range of offerings, catering to various client needs while fostering innovation through competition. In October Wuxi Biologics (China) announced the opening of a new state-of-the-art manufacturing facility aimed at increasing its production capacity for biosimilars. This strategic move is likely to enhance its competitive edge by enabling faster delivery times and meeting the growing demand for biosimilars in both domestic and international markets. The facility is expected to incorporate advanced technologies, which may further solidify Wuxi's reputation for quality and efficiency. In September Samsung Biologics (Korea) entered into a strategic partnership with a leading pharmaceutical company to co-develop a new biosimilar product. This collaboration is indicative of Samsung's strategy to leverage external expertise while expanding its product portfolio. Such partnerships may not only enhance Samsung's innovation capabilities but also position it favorably in a market that increasingly values collaborative approaches to development. In August Lonza Group (Switzerland) announced a significant investment in digital transformation initiatives aimed at streamlining its manufacturing processes. This investment reflects a broader trend within the industry towards integrating advanced technologies such as AI and automation. By enhancing operational efficiency, Lonza is likely to improve its competitive positioning, particularly in an environment where speed and adaptability are crucial. As of November the competitive trends in the biosimilar contract-manufacturing market are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances are becoming more prevalent, allowing companies to pool resources and expertise to navigate the complexities of the market. Looking ahead, it appears that competitive differentiation will evolve from traditional price-based competition to a focus on innovation, technological advancement, and supply chain reliability. This shift may ultimately redefine the landscape, emphasizing the importance of quality and efficiency in meeting the needs of a rapidly changing market. ## Recent News & Developments Recent developments in the China Biosimilar Contract Manufacturing Market have highlighted significant activities among key players. In July 2023, Changchun High and New Technology Industry announced the expansion of its biosimilar production facilities to enhance its manufacturing capacity, driven by increasing global demand for affordable biologics. Livzon Pharmaceutical continues to invest in Research and Development to strengthen its biosimilar portfolio, particularly in oncology products. WuXi AppTec has recently forged partnerships with international biopharmaceutical companies to facilitate clinical trials for multiple biosimilars. Additionally, in August 2023, Qilu Pharmaceutical reported a collaboration with Samsung BioLogics focused on the production of monoclonal antibodies, aiming to expand in the global biosimilar market. Notably, in March 2022, Hualan Biological Engineering completed the acquisition of a majority stake in ST Pharm, enhancing its capabilities in biosimilar production. The biosimilar market in China is projected to grow substantially, powered by advancements in technology and increased regulatory support from the National Medical Products Administration, fostering a more competitive landscape. Despite challenges, the push towards affordable therapeutics is reshaping the market, positioning companies like 3SBio and HengRui Medicine favorably for future opportunities. ## Report Scope | MARKET SIZE 2024 | 405.75(USD Million) | | --- | --- | | MARKET SIZE 2025 | 482.44(USD Million) | | MARKET SIZE 2035 | 2725.13(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 18.9% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Samsung Biologics (KR), Lonza Group (CH), Boehringer Ingelheim (DE), Fujifilm Diosynth Biotechnologies (JP), Catalent (US), Wuxi Biologics (CN), Rentschler Biopharma (DE), KBI Biopharma (US), Amgen (US) | | Segments Covered | Product, Production Technology, Application | | Key Market Opportunities | Emerging technologies in bioprocessing enhance efficiency in the biosimilar contract-manufacturing market. | | Key Market Dynamics | Rising demand for cost-effective biosimilars drives competitive contract-manufacturing partnerships in China. | | Countries Covered | China | ## Frequently Asked Questions **Q: What was the market valuation of the China biosimilar contract-manufacturing market in 2024?** A: The market valuation was $405.75 Million in 2024. **Q: What is the projected market valuation for the China biosimilar contract-manufacturing market by 2035?** A: The projected market valuation for 2035 is $2725.13 Million. **Q: What is the expected CAGR for the China biosimilar contract-manufacturing market during the forecast period 2025 - 2035?** A: The expected CAGR during the forecast period 2025 - 2035 is 18.9%. **Q: Which companies are considered key players in the China biosimilar contract-manufacturing market?** A: Key players include Samsung Biologics, Lonza Group, Boehringer Ingelheim, Fujifilm Diosynth Biotechnologies, Catalent, Wuxi Biologics, Rentschler Biopharma, KBI Biopharma, and Amgen. **Q: What were the valuations for recombinant glycosylated proteins in the China biosimilar contract-manufacturing market?** A: The valuations for recombinant glycosylated proteins ranged from $255.75 Million to $1875.13 Million. **Q: What is the market size for mammalian production technology in the China biosimilar contract-manufacturing market?** A: The market size for mammalian production technology was between $250.0 Million and $1700.0 Million. **Q: What applications are driving growth in the China biosimilar contract-manufacturing market?** A: Applications driving growth include oncology, blood disorders, chronic & autoimmune disorders, and rheumatoid arthritis. **Q: What was the valuation for chronic & autoimmune disorders in the China biosimilar contract-manufacturing market?** A: The valuation for chronic & autoimmune disorders was between $80.0 Million and $600.0 Million. **Q: How do recombinant non-glycosylated proteins compare to recombinant glycosylated proteins in terms of market valuation?** A: Recombinant non-glycosylated proteins had valuations from $150.0 Million to $850.0 Million, which is lower than the range for recombinant glycosylated proteins. **Q: What is the significance of the projected growth in the China biosimilar contract-manufacturing market?** A: The projected growth indicates a robust expansion, with the market expected to reach $2725.13 Million by 2035, reflecting increasing demand and investment. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/china-biosimilar-contract-manufacturing-market-51874*